Free Trial
NASDAQ:CVKD

Cadrenal Therapeutics Q4 2024 Earnings Report

Cadrenal Therapeutics logo
$14.75 -0.28 (-1.86%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$14.72 -0.03 (-0.20%)
As of 05/23/2025 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cadrenal Therapeutics EPS Results

Actual EPS
-$2.74
Consensus EPS
-$1.71
Beat/Miss
Missed by -$1.03
One Year Ago EPS
N/A

Cadrenal Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cadrenal Therapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Thursday, March 13, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Cadrenal Therapeutics' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Cadrenal Therapeutics Earnings Headlines

What is Zacks Small Cap's Estimate for CVKD FY2025 Earnings?
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... This is what President Trump said: "Our currency is crashing and will soon no longer be the world standard, which will be our greatest defeat, frankly, in 200 years." Why Would He Say This?
See More Cadrenal Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cadrenal Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cadrenal Therapeutics and other key companies, straight to your email.

About Cadrenal Therapeutics

Cadrenal Therapeutics (NASDAQ:CVKD) operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

View Cadrenal Therapeutics Profile

More Earnings Resources from MarketBeat